<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11609">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01932606</url>
  </required_header>
  <id_info>
    <org_study_id>13-004077</org_study_id>
    <nct_id>NCT01932606</nct_id>
  </id_info>
  <brief_title>Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction</brief_title>
  <official_title>Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barry Borlaug</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure with preserved ejection fraction (HFpEF) is a major public health problem that
      has no proven effective treatment.  This study will assess the effects of acute nitrite
      administration on resting and exercise hemodynamics in patients with HFpEF referred to the
      catheterization lab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Exercise pulmonary capillary wedge pressure</measure>
    <time_frame>during repeat exercise run, approximately 30 minutes after study drug administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Disease</condition>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <condition>Exercise Intolerance</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Nitrite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Placebo for Nitrite will be infused for 5 minutes during the cardiac catheterization procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrite</intervention_name>
    <description>Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.</description>
    <arm_group_label>Nitrite</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Placebo for Nitrite</intervention_name>
    <description>Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure.  Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled to undergo a cardiac catheterization procedure.

          -  Clinical symptoms of shortness of breath and fatigue

          -  Normal left ventricular ejection fraction (≥50%)

          -  Elevated left ventricular filling pressures at cardiac catheterization (defined as
             resting PCWP&gt;15 mmHg and/or PCWP≥25 mmHg during exercise)

        Exclusion Criteria:

          -  Systolic BP &lt;120 mmHg

          -  Prior nitrate therapy (within previous 2 weeks)

          -  G6PD-deficiency

          -  Other &quot;non-HFpEF&quot; specific causes of heart failure such as significant valvular
             disease (&gt;moderate left-sided regurgitation, &gt;mild stenosis), severe pulmonary
             disease, unstable coronary disease or coronary spasm, primary renal or hepatic
             disease, constrictive pericarditis, or infiltrative, restrictive, or hypertrophic
             cardiomyopathies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry Borlaug, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barry A Borlaug, MD</last_name>
    <phone>50728442</phone>
    <email>borlaug.barry@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Bruhn</last_name>
      <phone>507-255-7100</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>August 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Barry Borlaug</investigator_full_name>
    <investigator_title>M.D., Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
